(Reuters) – Medical instrument producer Dexcom beat Wall Street approximates for third-quarter earnings on Thursday, aided by sturdy want for its fixed sugar screens for diabetic points people.
However, the enterprise acknowledged its full-year gross sales projection of concerning $4 billion to $4.05 billion, sending its shares decreases nearly 16% after the bell.
Dexcom claimed Chief Commercial Officer Teri Lawver would definitely retire on the finish of the yr.
The enterprise in July lowered its yearly earnings projection, criticizing a restructuring of its gross sales group, much less purchasers, and lowered earnings from every shopper, sending its shares to a four-year lowered. Shares are down 40% till now this yr.
Dexcom reported third-quarter earnings of $994.2 million, defeating consultants’ worth quotes of $990.7 million, in accordance info from LSEG.
(Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila)
